The US Food and Drug Administration today expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, albumin-bound) to treat patients with late-stage (metastatic) pancreatic cancer.

On Thursday, the U.S. Food and Drug Administration (FDA) approved Afinitor ( everolimus ) to treat patients with progressive neuroendocrine tumors located in the pancreas ( PNET ) that cannot be removed by surgery or that have spread to other parts of the body (metastatic).